Showing 61 - 80 results of 182 for search '"Yinchuan"', query time: 0.05s Refine Results
  1. 61
  2. 62
  3. 63

    The Association Between Mitral Regurgitation and Long-Term Outcomes in Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Retrospective Large Sample Cohor... by Yan N, Wu P, Zhu B, Ma A, Wang X, Hai X, Ma X, Jiang H, Yang S

    Published 2025-02-01
    “…Ning Yan,1,* Peng Wu,1,2,* Baozhen Zhu,2,3 Ali Ma,2 Xin Wang,2 Xinrui Hai,2 Xueping Ma,1 Hao Jiang,4 Shaobin Yang1 1Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia Medical University, Yinchuan, People’s Republic of China; 2The First Clinical College of Ningxia Medical University, Yinchuan, People’s Republic of China; 3Department of Intervention, Tong Xin City People’s Hospital, Yinchuan, People’s Republic of China; 4Department of Cardiology, Yinchuan Hospital of Traditional Chinese Medicine, Yinchuan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hao Jiang, Department of Cardiology, Yinchuan Hospital of Traditional Chinese Medicine, Yinchuan, 750004, People’s Republic of China, Tel +18295496850, Email 18295496850@163.com Shaobin Yang, Heart Centre & Department of Cardiovascular Diseases, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, People’s Republic of China, Tel +8613895625229, Email youngshb@126.comBackground: The relationship between mitral regurgitation (MR) and long-term outcomes in Chinese patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) remains scarce. …”
    Get full text
    Article
  4. 64
  5. 65
  6. 66
  7. 67
  8. 68
  9. 69
  10. 70

    Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension by Liu H, Liu S, Ma P, Ma L, Liu Y, Zhao F, Zhou R

    Published 2025-01-01
    “…Hui Liu,1,* Siyun Liu,1,* Pengsheng Ma,1 Long Ma,1 Yuxin Liu,1 Fang Zhao,2 Ru Zhou1,3,4 1School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China; 2General Hospital of Ningxia Medical University, Yinchuan, 750004, People’s Republic of China; 3NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China; 4Ningxia Characteristic Traditional Chinese Medicine Modernization Engineering Technology Research Center, Ningxia Medical University, Yinchuan, 750004, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ru Zhou, School of Pharmacy, Ningxia Medical University, Xingqing, Ningxia, Yinchuan, 750004, People’s Republic of China, Email zhou-ru926@163.com Fang Zhao, General Hospital of Ningxia Medical University, Xingqing, Ningxia, Yinchuan, 750004, People’s Republic of China, Email ysj119zf@163.comObjective: This study focuses on the development and evaluation of nanostructured lipid carriers (NLCs) loaded with aloperine as a potential therapeutic approach for the treatment of pulmonary arterial hypertension.Methods: The NLCs were designed to enhance the solubility, stability, and bioavailability of aloperine, a compound with vasodilatory and anti-inflammatory properties. …”
    Get full text
    Article
  11. 71
  12. 72
  13. 73
  14. 74
  15. 75
  16. 76
  17. 77
  18. 78
  19. 79
  20. 80